| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 9, 2021~ Largest gene therapy study in hemophilia B achieved primary endpoint of non-inferiority in annualized bleeding rate after stable Factor IX (FIX) expression, assessed at 18 months following a single dose of etranacogene dezaparvovec
Lexington, MA and Amsterdam, the Netherlands, King of Prussia, PA , December 9, 2021 — CSL Behring, a global biotherapeutics leader, and uniQure N.V. (NASDAQ: QURE), a leading gene therapy...
-
Oct 19, 2021• CSL advances novel pipeline spanning six therapeutic areas, four scientific platforms and two businesses (CSL Behring and Seqirus)
MELBOURNE, AU and KING OF PRUSSIA, PA; October 19/18, 2021 – During its annual R&D investment briefing earlier today, CSL Limited (ASX:CSL; USOTC:CSLLY) highlighted progress from its novel...
-
Oct 5, 2021CSL introduced a scholarship program for U.S. employees and their dependents as part of delivering on its promise to diversity, equity and inclusion.
CSL introduced a scholarship program for U.S. employees and their dependents as part of delivering on its promise to diversity, equity and inclusion. 05 Oct 2021 Global biotech leader CSL has...
-
Sep 17, 2021Here's how CSL is working around the world with academia, industry and governments to combat COVID-19
CSL has remained agile to stay ahead of the pandemic challenges and has redirected resources to where it can add the most value to address the pandemic challenges. From the time the coronavirus...
Sep 11, 2021Global biotech leader CSL and the Urban League of Philadelphia are working to address some of the most pressing needs in the community, including efforts to strengthen Public Health, Leadership Development, Workforce Diversity and Job Creation and Training.Global biotech leader CSL and the Urban League of Philadelphia are working to address some of the most pressing needs in the community, including efforts to strengthen Public Health, Leadership...
-
Aug 9, 2021The updated guideline empowers physicians with the confidence to expand the treatment options prescribed for CIDP patients
The updated guideline empowers physicians with the confidence to expand the treatment options prescribed for CIDP patients 09 Aug 2021 KING OF PRUSSIA, Pa. – Aug. 9, 2021 – Global...
-
Aug 3, 2021Approval received to co-package a convenience administration kit along with the product BERINERT.
KING OF PRUSSIA, PA 03 Aug 2021 CSL Behring, a global biotherapeutics leader received U.S. Food and Drug Administration (FDA) approval for its supplemental request (submitted Aug. 30, 2020) for...
-
Jun 8, 2021Hizentra will be covered under the same Medicare benefit category as intravenous immune globulin (IVIg), but with the convenience of self-infusing at home
KING OF PRUSSIA, Pa. 08 Jun 2021 Global biotherapeutics leader CSL Behring today announced that the Centers for Medicare & Medicaid Services (CMS) has approved Hizentra for coverage under Medicare...
-
Jun 2, 2021CSL continues to provide medicines to patients around the world.
Safeguarding our people, patients and donors remains our top priority. As the COVID-19 pandemic evolves, CSL continues to provide medicines to patients around the world. We’re also exploring new...
-
May 16, 2021Findings signal need for novel treatment strategies to provide more protection during this high-risk, 90-day period
KING OF PRUSSIA, Pa. 16 May 2021 Global biotherapeutics leader CSL Behring today announced the results of a new meta-analysis of seven interventional Phase 3 clinical trials that included more...